



DataHow Symposium

Al-Driven Biomanufacturing: From Predictive Model to Adaptive Shop Floor Ecosystem

Hadj Latreche

Head Digital, Operational Excellence & Innovation

26th June 2025

Key paradigm shifts in the way we design & deploy Al



A holistic focus on business, technology and people enables transformative impact







The why?

Setting the Context and Expected Outcomes

Titer Variability ranges from 5% to 30% leading to significant lost of API and potential value of 60+mCHF/Year at scale








Unexpected Critical Quality Attributes (CQAs) Deviations have tremendous business and financial impact







CQAs deviations lead to batch write-off and are usually requiring intense and long effort for remediations

Business Opportunity

Right First Time

Optimised resource investment

Robust Supply to Patient

Financial / KPIs Opportunity

-30%

cost related to write-offs

-40%

resources related to recurring issues

> 97%

OTIF (On Time In Full)



The what?

From a fragmented data landscape to an adaptive shopfloor

We have developed an AI based Control of Product Health solution improving yield by +10% and managing multi-variate complexities




Complex biological manufacturing process




10 mfg steps over 30 -40 days

5-30% variability between batches




We create and sustain value with going through the entire AI value chain and creating a capability ecosystem




How does our digital App Suites look like?





Al driven Digital Ecosystem and Capabilities








The How?

Defining our Operating & Staffing Model

We developed a standard deployment process





We developed Data Pipeline in a dispersed Data Landscape...





PI System



(Manufacturing Execution System)










We built most relevant features with multiple parameters... Feature B Feature C Feature D Feature E Target 0 Given hundreds of measurements Corr.: Corr.: Corr.: Corr.: 0.317*** 0.644*** -0.333*** 0.266*** -0.153* -0.053 performed for each batch, it is essential to consider multiple Corr.: Corr.: 0.366*** -0.233*** -0.144* 0.149* 0.249*** features at once. This also allows to characterize association between Corr.: Corr.: Corr.: features 0.160* -0.373*** -0.022 0.187** Deep dive Corr.: Corr.: Corr.: -0.188** -0.051 -0.142* Corr.: Corr.: 0.069 -0.161* **Feature** extraction Strong correlations

We had to deal process scale comparability...

How well do the scales compare based on offline/online process data?






Comparable Scales enable leveraging and combining process development and commercial manufacturing data

We evaluate carefully our Model evaluation prediction strenght



Having the predicted titer closely match the measured titer should not be the (only) way of measuring model performance – it is more desirable to focus on impact of features and generalization



Ideally, one would like

Predicted titer ≅ Measured titer

in terms of similarity metrics (R², RMSE).

But one would also like to:

- → Retain only impactful features
- Avoid overfitting
- Make sure the trained model is able to generalize to new batches




Scaling in regulated environment

From "toys" to GMP compliant tools

Scaling Readiness and Challenges to overcome





Influencing Factors

- Data Backbone readiness
- Data Connectivity
- Data Quality
- Key Process Data availability
- New Analytical Technologies
- Accuracy Oversight
- End Users engagement and consideration during design
- Digital Maturity
- Transformation Standardisation
- Actions simplifications

GMP Impact Core Considerations...







No Data Generation





No alteration of manufacturing process (recommendation stays in validated ranges)






No automated (closed loop) decision

Continuous Model validation with continuous new testing data



By splitting the data into training and test data, we make sure that our model is able to generalize (predict) to an independent dataset coming from new batches



WEF announcement Oct 8th, 2024

Roche Basel Drug
Substance
Manufacturing has
been recognized as a
"Global Digital
Lighthouse Factory"
by the World
Economic Forum

